BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30343166)

  • 1. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
    Chandler H; Lanske B; Varela A; Guillot M; Boyer M; Brown J; Pierce A; Ominsky M; Mitlak B; Baron R; Kostenuik P; Hattersley G
    Bone; 2019 Mar; 120():148-155. PubMed ID: 30343166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
    Besschetnova T; Brooks DJ; Hu D; Nagano K; Nustad J; Ominsky M; Mitlak B; Hattersley G; Bouxsein ML; Baron R; Lanske B
    Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
    Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
    J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
    Chandler H; Brooks DJ; Hattersley G; Bouxsein ML; Lanske B
    Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
    Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
    Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
    Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
    Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
    Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
    Varela A; Chouinard L; Lesage E; Guldberg R; Smith SY; Kostenuik PJ; Hattersley G
    Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading.
    Teguh DA; Nustad JL; Craven AE; Brooks DJ; Arlt H; Hu D; Baron R; Lanske B; Bouxsein ML
    Bone; 2021 Mar; 144():115801. PubMed ID: 33338664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture.
    Lanske B; Chandler H; Pierce A; Brown J; Ominsky M; Kostenuik P; Hattersley G
    J Orthop Res; 2019 Apr; 37(4):812-820. PubMed ID: 30790359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens have antiresorptive effects on trabecular disuse osteopenia independent from muscle atrophy.
    Laurent MR; Jardí F; Dubois V; Schollaert D; Khalil R; Gielen E; Carmeliet G; Claessens F; Vanderschueren D
    Bone; 2016 Dec; 93():33-42. PubMed ID: 27622887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats.
    Gabet Y; Kohavi D; Müller R; Chorev M; Bab I
    Osteoporos Int; 2005 Nov; 16(11):1436-43. PubMed ID: 15812598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.
    Le Henaff C; Ricarte F; Finnie B; He Z; Johnson J; Warshaw J; Kolupaeva V; Partridge NC
    J Bone Miner Res; 2020 Apr; 35(4):714-724. PubMed ID: 31793033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats.
    Gunness M; Orwoll E
    J Bone Miner Res; 1995 Nov; 10(11):1735-44. PubMed ID: 8592951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.
    Hopson MB; Onishi M; Awad D; Buono D; Maurer M; Crew KD; Shane E; Hershman DL; Kalinsky K
    Clin Breast Cancer; 2020 Jun; 20(3):e327-e333. PubMed ID: 31926840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
    Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
    Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat.
    Tezval M; Serferaz G; Rack T; Kolios L; Sehmisch S; Schmelz U; Tezval H; Stuermer KM; Stuermer EK
    World J Urol; 2011 Aug; 29(4):529-34. PubMed ID: 21298272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.